Aurobindo’s Dazublys Gets EU Green Light: Biosimilar Set to Transform HER2+ Cancer Care

Unknown Apr 02, 2026 700 Views

Aurobindo Pharma has secured a major regulatory milestone with the European Commission granting marketing approval for Dazublys, its trastuzumab biosimilar, developed by subsidiary CuraTeQ Biologics. The approval follows a positive opinion from the European Medicines Agency’s CHMP in April...